Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.51 |
| ▸ | MAOB | P27338 | 4/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6799095 | 0.96 | ACHE (0.53) | ACHEMAOBHRH3ESR1ESR2 | |
| SCHEMBL6802385 | 0.90 | ACHE (0.51) | ACHEMAOBHRH3ESR1ESR2 | |
| SCHEMBL6806644 | 0.90 | ACHE (0.51) | ACHEMAOBHRH3ESR1ESR2 | |
| SCHEMBL6799216 | 0.90 | ACHE (0.51) | ACHEMAOBHRH3ESR1ESR2 | |
| SCHEMBL6800759 | 0.88 | ESR1 (0.47) | ACHEMAOBHRH3ESR1ESR2 | |
| SCHEMBL6798806 | 0.86 | ESR1 (0.51) | HRH3ESR1ESR2 | |
| SCHEMBL6796017 | 0.82 | HRH3 (0.49) | ACHEMAOBHRH3 | |
| SCHEMBL6799341 | 0.80 | ESR1 (0.52) | HRH3ESR1ESR2 | |
| SCHEMBL6796544 | 0.79 | ESR1 (0.57) | HRH3ESR1ESR2 | |
| SCHEMBL6796784 | 0.76 | HRH3 (0.57) | ACHEMAOBHRH3ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082642-A1 | Novel estrogen receptor ligands and method III | MERCK & CO., INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082642-A1 | Novel estrogen receptor ligands and method III | ESRRA, ESRRB, FSHR | ACHE 689/4885MAOB 1020/4885HRH3 892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.